Athersys

Athersys

A biopharmaceutical company developing therapeutic products for the treatment of diseases.

Cleveland biotechnology company Athersys Inc received Fast Track designation from the U.S. Food and Drug Administration in acute respiratory distress syndrome, or ARDS.

In January 2019,the company ran a randomized, double-blind placebo-controlled exploratory Phase 2 clinical study evaluating MultiStem administration to patients with ARDS.

In the study, patients who received MultiStem treatment within several days after being diagnosed with ARDS and being placed on a ventilator experienced lower mortality, increased ventilator-free days, and increased ICU-free days during the initial 28-day clinical assessment period relative to patients receiving placebo.

Athersys' partner in Japan, Healios K.K., enrolled patients in a clinical trial evaluating administration of MultiStem to pneumonia-induced ARDS patients in Japan.

Timeline

1995

Athersys was founded.

People

Name
Role
LinkedIn

Anthony Ting

Employee

Garrett Van Wagoner

Investor

Jason Zilles

Employee

Jim Kovach

Employee

Marc DePaul

Employee

Norbert Varga

Employee

Further reading

Title
Author
Link
Type
Date

Athersys Inc. extends agreement with Healios for a license to MultiStem therapy for indications in China

Scott Suttell

Web

Athersys: A Lucrative China Stem Cell Licensing Deal Seems Imminent

Seekingalpha

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.